Floatz logo

LETAPLIMAB

Advanced Malignancies

Innovent Biologics (Suzhou) Co. Ltd.monoclonal_antibodyPhase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
89/ 100

Competitive context

1412 Active assets in the Advanced Malignancies cohort.

Asset / SponsorPhaseRating
Nabiximols
Jazz Pharmaceuticals
Phase 3BBB
Vitamin B6
M.D. Anderson Cancer Center
Phase 4BB
Inno-206
M.D. Anderson Cancer Center
Phase 2BB
PROPOFOL
Hong Kong Children's Hospital
Phase 4BB
Rivoceranib
Jiangsu HengRui Medicine Co., Ltd.
Phase 4BB

View all 50 →

Same molecule, other indications

LETAPLIMAB is also rated in:

lung adenocarcinomaDormant
C
Indicative ·
37 / 100
View asset →
osteosarcomaDormant
C
Indicative ·
37 / 100
View asset →
acute myeloid leukemiaDormant
C
Indicative ·
34 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →